First-in-Human Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Ascending Doses of ARV-102, a PROTAC LRRK2 Degrader, in Healthy Participants Date & Time : Oct.

Now, researchers have created a new method called Advanced Sensing of Aggregates for Parkinson’s Disease (ASA-PD), which uses ...

Phase 2 ASCEND trial of solengepras, a novel, non-dopaminergic GPR6 inhibitor, showed evidence of potential benefit in ...

Researchers at the University of Bath, in collaboration with the Universities of Oxford and Bristol, have developed a ...

Gain Therapeutics, Inc., a clinical-stage biotechnology company, announced that it will present its lead drug candidate, GT-02287, at the International Association of Parkinsonism and Related ...

For more than a decade, Carnegie Mellon neuroscientist Aryn Gittis has been unraveling the mystery of how the brain controls movement — research now pointing toward new treatments for Parkinson’s ...

The toxins could potentially be used as ‘markers’ for doctors to identify Parkinson’s patients at a higher risk of developing dementia ...

ABLi Therapeutics (“ABLi”), a biotechnology company developing therapeutics to address diseases that arise from activation of Abelson Tyrosine Kinases (c-Abl kinases), announces that the final results ...

Scientists have, for the first time, directly visualised and quantified the protein clusters believed to trigger Parkinson’s, marking a major advance in the study of the world’s fastest-growing ...

Gandhi and colleagues reported on their findings in Nature Biomedical Engineering, in a paper titled “ Large-scale visualization of α-synuclein oligomers in Parkinson’s disease brain tissue ,” in ...

Session: Oral Poster Presentation – Guided Poster TourSession Date: Saturday, May 10, 2025Session Time: 8:00-9:00 a.m. EST About GT-02287Gain Therapeutics’ lead drug candidate, GT-02287, is in ...